Comprehensive genomic profiling AIDS in treatment of a metastatic endometrial cancer

Jatinder Dhami, Kim Hirshfield, Shridar Ganesan, Mira Hellmann, Veronica Rojas, Judith Amorosa, Gregory M. Riedlinger, Hua Zhong, Siraj M. Ali, Dean Pavlick, Julia A. Elvin, Lorna Rodriguez-Rust

Research output: Contribution to journalArticle

Abstract

FGFR-TACC fusions, including FGFR3-TACC3, have been identified as potential oncogenic drivers and actionable alterations in a number of different cancer types. The clinical relevance of FGFR3-TACC3 fusions in endometrial cancer has not yet been described. Formalin-fixed, paraffin-embedded metastatic endometrial carcinoma from the spleen and peritoneum were sent for comprehensive genomic profiling (CGP) using the FoundationOne platform as part of a prospective tumor genomic profiling protocol. We report the identification of an FGFR3-TACC3 fusion in a case of metastatic endometrioid endometrial cancer. Other potentially actionable alterations detected in this specimen included PIK3CA T1025S and an uncharacterized rearrangement involving TSC2. The patient initially received an FGFR inhibitor as an investigational agent and experienced stable disease with complete resolution of a pelvic nodule; however, treatment had to be discontinued because of intolerable side effects. A PET/CT scan nearly 3 mo after discontinuation showed disease progression. She subsequently received the mTOR inhibitor, temsirolimus, later accompanied by letrozole, and achieved stable disease. Clinical benefit was attributed to the mTOR inhibitor as tumor stained negative for estrogen receptor. Temsirolimus was discontinued after >17 mo because of disease progression. FGFR inhibitors may have clinical benefit in the treatment of endometrial carcinoma with FGFR3-TACC3 fusions. Additionally, clinical benefit from an mTOR inhibitor may reflect a response to targeting the alteration in PIK3CA or TSC2. More research is needed to understand the activity of FGFR3-TACC3 fusions on tumors and to discover additional therapeutic options for endometrial carcinoma patients with this gene fusion.

Original languageEnglish (US)
Article numbera002089
JournalCold Spring Harbor Molecular Case Studies
Volume4
Issue number2
DOIs
StatePublished - Apr 1 2018

Fingerprint

Endometrial Neoplasms
Acquired Immunodeficiency Syndrome
letrozole
Disease Progression
Neoplasms
Therapeutics
Gene Fusion
Peritoneum
Estrogen Receptors
Paraffin
Formaldehyde
Spleen
Research
temsirolimus

All Science Journal Classification (ASJC) codes

  • Genetics(clinical)
  • Genetics
  • Molecular Medicine
  • Biochemistry

Cite this

Dhami, Jatinder ; Hirshfield, Kim ; Ganesan, Shridar ; Hellmann, Mira ; Rojas, Veronica ; Amorosa, Judith ; Riedlinger, Gregory M. ; Zhong, Hua ; Ali, Siraj M. ; Pavlick, Dean ; Elvin, Julia A. ; Rodriguez-Rust, Lorna. / Comprehensive genomic profiling AIDS in treatment of a metastatic endometrial cancer. In: Cold Spring Harbor Molecular Case Studies. 2018 ; Vol. 4, No. 2.
@article{9a6c63c430ae469f860a8687c69fd30e,
title = "Comprehensive genomic profiling AIDS in treatment of a metastatic endometrial cancer",
abstract = "FGFR-TACC fusions, including FGFR3-TACC3, have been identified as potential oncogenic drivers and actionable alterations in a number of different cancer types. The clinical relevance of FGFR3-TACC3 fusions in endometrial cancer has not yet been described. Formalin-fixed, paraffin-embedded metastatic endometrial carcinoma from the spleen and peritoneum were sent for comprehensive genomic profiling (CGP) using the FoundationOne platform as part of a prospective tumor genomic profiling protocol. We report the identification of an FGFR3-TACC3 fusion in a case of metastatic endometrioid endometrial cancer. Other potentially actionable alterations detected in this specimen included PIK3CA T1025S and an uncharacterized rearrangement involving TSC2. The patient initially received an FGFR inhibitor as an investigational agent and experienced stable disease with complete resolution of a pelvic nodule; however, treatment had to be discontinued because of intolerable side effects. A PET/CT scan nearly 3 mo after discontinuation showed disease progression. She subsequently received the mTOR inhibitor, temsirolimus, later accompanied by letrozole, and achieved stable disease. Clinical benefit was attributed to the mTOR inhibitor as tumor stained negative for estrogen receptor. Temsirolimus was discontinued after >17 mo because of disease progression. FGFR inhibitors may have clinical benefit in the treatment of endometrial carcinoma with FGFR3-TACC3 fusions. Additionally, clinical benefit from an mTOR inhibitor may reflect a response to targeting the alteration in PIK3CA or TSC2. More research is needed to understand the activity of FGFR3-TACC3 fusions on tumors and to discover additional therapeutic options for endometrial carcinoma patients with this gene fusion.",
author = "Jatinder Dhami and Kim Hirshfield and Shridar Ganesan and Mira Hellmann and Veronica Rojas and Judith Amorosa and Riedlinger, {Gregory M.} and Hua Zhong and Ali, {Siraj M.} and Dean Pavlick and Elvin, {Julia A.} and Lorna Rodriguez-Rust",
year = "2018",
month = "4",
day = "1",
doi = "https://doi.org/10.1101/mcs.a002089",
language = "English (US)",
volume = "4",
journal = "Cold Spring Harbor molecular case studies",
issn = "2373-2873",
publisher = "Cold Spring Harbor Laboratory Press",
number = "2",

}

Comprehensive genomic profiling AIDS in treatment of a metastatic endometrial cancer. / Dhami, Jatinder; Hirshfield, Kim; Ganesan, Shridar; Hellmann, Mira; Rojas, Veronica; Amorosa, Judith; Riedlinger, Gregory M.; Zhong, Hua; Ali, Siraj M.; Pavlick, Dean; Elvin, Julia A.; Rodriguez-Rust, Lorna.

In: Cold Spring Harbor Molecular Case Studies, Vol. 4, No. 2, a002089, 01.04.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comprehensive genomic profiling AIDS in treatment of a metastatic endometrial cancer

AU - Dhami, Jatinder

AU - Hirshfield, Kim

AU - Ganesan, Shridar

AU - Hellmann, Mira

AU - Rojas, Veronica

AU - Amorosa, Judith

AU - Riedlinger, Gregory M.

AU - Zhong, Hua

AU - Ali, Siraj M.

AU - Pavlick, Dean

AU - Elvin, Julia A.

AU - Rodriguez-Rust, Lorna

PY - 2018/4/1

Y1 - 2018/4/1

N2 - FGFR-TACC fusions, including FGFR3-TACC3, have been identified as potential oncogenic drivers and actionable alterations in a number of different cancer types. The clinical relevance of FGFR3-TACC3 fusions in endometrial cancer has not yet been described. Formalin-fixed, paraffin-embedded metastatic endometrial carcinoma from the spleen and peritoneum were sent for comprehensive genomic profiling (CGP) using the FoundationOne platform as part of a prospective tumor genomic profiling protocol. We report the identification of an FGFR3-TACC3 fusion in a case of metastatic endometrioid endometrial cancer. Other potentially actionable alterations detected in this specimen included PIK3CA T1025S and an uncharacterized rearrangement involving TSC2. The patient initially received an FGFR inhibitor as an investigational agent and experienced stable disease with complete resolution of a pelvic nodule; however, treatment had to be discontinued because of intolerable side effects. A PET/CT scan nearly 3 mo after discontinuation showed disease progression. She subsequently received the mTOR inhibitor, temsirolimus, later accompanied by letrozole, and achieved stable disease. Clinical benefit was attributed to the mTOR inhibitor as tumor stained negative for estrogen receptor. Temsirolimus was discontinued after >17 mo because of disease progression. FGFR inhibitors may have clinical benefit in the treatment of endometrial carcinoma with FGFR3-TACC3 fusions. Additionally, clinical benefit from an mTOR inhibitor may reflect a response to targeting the alteration in PIK3CA or TSC2. More research is needed to understand the activity of FGFR3-TACC3 fusions on tumors and to discover additional therapeutic options for endometrial carcinoma patients with this gene fusion.

AB - FGFR-TACC fusions, including FGFR3-TACC3, have been identified as potential oncogenic drivers and actionable alterations in a number of different cancer types. The clinical relevance of FGFR3-TACC3 fusions in endometrial cancer has not yet been described. Formalin-fixed, paraffin-embedded metastatic endometrial carcinoma from the spleen and peritoneum were sent for comprehensive genomic profiling (CGP) using the FoundationOne platform as part of a prospective tumor genomic profiling protocol. We report the identification of an FGFR3-TACC3 fusion in a case of metastatic endometrioid endometrial cancer. Other potentially actionable alterations detected in this specimen included PIK3CA T1025S and an uncharacterized rearrangement involving TSC2. The patient initially received an FGFR inhibitor as an investigational agent and experienced stable disease with complete resolution of a pelvic nodule; however, treatment had to be discontinued because of intolerable side effects. A PET/CT scan nearly 3 mo after discontinuation showed disease progression. She subsequently received the mTOR inhibitor, temsirolimus, later accompanied by letrozole, and achieved stable disease. Clinical benefit was attributed to the mTOR inhibitor as tumor stained negative for estrogen receptor. Temsirolimus was discontinued after >17 mo because of disease progression. FGFR inhibitors may have clinical benefit in the treatment of endometrial carcinoma with FGFR3-TACC3 fusions. Additionally, clinical benefit from an mTOR inhibitor may reflect a response to targeting the alteration in PIK3CA or TSC2. More research is needed to understand the activity of FGFR3-TACC3 fusions on tumors and to discover additional therapeutic options for endometrial carcinoma patients with this gene fusion.

UR - http://www.scopus.com/inward/record.url?scp=85054776086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054776086&partnerID=8YFLogxK

U2 - https://doi.org/10.1101/mcs.a002089

DO - https://doi.org/10.1101/mcs.a002089

M3 - Article

VL - 4

JO - Cold Spring Harbor molecular case studies

JF - Cold Spring Harbor molecular case studies

SN - 2373-2873

IS - 2

M1 - a002089

ER -